Ginkgo Bioworks Holdings (DNA) Depreciation & Amortization (CF) (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) posted Depreciation & Amortization (CF) of $12.8 million for Q1 2026, down 6.32% on a QoQ basis from $13.7 million in Q4 2025, and down 13.65% year-over-year from $14.8 million in Q1 2025.
Ginkgo Bioworks Holdings (DNA) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $12.8 million for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 13.65% year-over-year to $12.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.4 million (down 13.16% YoY) and the FY2025 annual result came in at $59.0 million, down 6.39% from the prior year.
- Depreciation & Amortization (CF) was $12.8 million for Q1 2026 at Ginkgo Bioworks Holdings, down from $13.7 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $21.1 million in Q3 2023 and bottomed at $8.9 million in Q3 2022.
- A 5-year average of $14.5 million and a median of $14.8 million in 2025 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) surged 136.18% — and 2024, when it slumped 32.12%.
- Ginkgo Bioworks Holdings' Depreciation & Amortization (CF) stood at $15.7 million in 2022, then retreated by 18.06% to $12.8 million in 2023, then increased by 21.93% to $15.7 million in 2024, then slipped by 12.71% to $13.7 million in 2025, then slipped by 6.32% to $12.8 million in 2026.
- Business Quant data shows DNA's Depreciation & Amortization (CF) at $12.8 million in Q1 2026, $13.7 million in Q4 2025, and $14.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Ginkgo Bioworks Holdings | 517.16 Mn | 373.30 Mn | 16.38 Mn | 12.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.80 Mn |
| Mar 31, 2026 | 12.80 Mn |
| Dec 31, 2025 | 13.66 Mn |
| Dec 31, 2025 | 13.66 Mn |
| Sep 30, 2025 | 14.17 Mn |
| Sep 30, 2025 | 14.17 Mn |
| Jun 30, 2025 | 15.79 Mn |
| Jun 30, 2025 | 15.79 Mn |
| Mar 31, 2025 | 14.82 Mn |
| Mar 31, 2025 | 14.82 Mn |
| Dec 31, 2024 | 15.65 Mn |
| Dec 31, 2024 | 15.65 Mn |
| Sep 30, 2024 | 17.17 Mn |
| Sep 30, 2024 | 17.17 Mn |
| Jun 30, 2024 | 17.33 Mn |
| Jun 30, 2024 | 17.33 Mn |
| Mar 31, 2024 | 12.87 Mn |
| Mar 31, 2024 | 12.87 Mn |
| Dec 31, 2023 | 12.84 Mn |
| Dec 31, 2023 | 12.84 Mn |